Epidemiology of Cervical Cancer

Carla Alves¹, Luís Alves¹,²,³, Nuno Lunet¹

ABSTRACT

Cervical cancer is the fifth most common cancer in European women. The recognition of a viral agent such as Human Papillomavirus (HPV) as a necessary cause in the development of cervical cancer implies that this disease may be prevented by effective prophylactic or therapeutic interventions against this infection. HPV vaccines conferring protection against infection with oncogenic HPV types 16 and 18, which cause the majority of the cervical cancer cases, are currently marketed, but continued cervical cancer screening is necessary regardless of vaccination. Organised screening programs have the highest potential to reduce cervical cancer mortality, by achieving higher levels of coverage of all population groups and higher proportions of women screened at regular intervals, with better cost-effectiveness and overall quality. Opportunistic screening, on the other hand, has a more limited impact and is more difficult to monitor and to evaluate due to its decentralized nature and lack of systematic reporting. However, opportunistic screening is still predominant in most European countries. In Portugal, cervical cancer screening has been predominantly opportunistic, except for regional organised programs in the Central Region of Portugal, in the region of Alentejo and an organised screening program is also being implemented in the North region of Portugal.

KEYWORDS: UTERINE CERVICAL NEOPLASM; EPIDEMIOLOGY; SCREENING

EPIEMIOLOGIA DO CANCRO DO COLO DO ÚTERO

RESUMO

O cancro do colo do útero é o quinto cancro mais frequente em mulheres europeias. A identificação do vírus do Papiloma humano como causa necessária para o desenvolvimento do cancro do colo do útero implica que esta doença possa ser prevenida pela implementação de medidas profiláticas ou terapêuticas efectivas dirigidas a esta infecção. Existem actualmente vacinas que conferem protecção contra a infecção pelos tipos de vírus do Papiloma humano oncogénicos responsáveis pela maioria dos cancros do colo do útero. Contudo, o rastreio do cancro do colo do útero continua a ser essencial para a prevenção e controlo deste cancro, e os programas de rastreio organizados têm um maior potencial para reduzir a mortalidade por cancro do colo do útero, proporcionando níveis de cobertura mais elevados em todos os grupos da população, em intervalos regulares, com uma melhor relação custo-eficácia e qualidade. O impacto do rastreio oportunista é mais limitado, sendo a qualidade deste tipo de actividades de rastreio mais difícil de avaliar devido à sua natureza descentralizada e à falta de recolha sistemática de toda a informação necessária para a avaliação. Contudo, os rastreios oportunistas representam ainda a única práctica de actividades de rastreio na maioria dos países europeus. Em Portugal, o rastreio do cancro do colo do útero tem sido predominantemente oportunista, excepto na região Centro e Alentejo, que dispõe de programas regionais de rastreio organizado e está a ser implementado o rastreio organizado também na região norte de Portugal.

PALAVRAS-CHAVE: CANCRO DO COLO DO ÚTERO; EPIDEMIOLOGIA; RASTREIO

1. Department of Hygiene and Epidemiology, Porto University Medical School, Porto, Portugal
2. Institute of Public Health – Porto University (ISUP), Porto, Portugal
3. St. André de Canidelo Health Family Unit, Vila Nova de Gaia, Portugal

BURDEN OF CERVICAL CANCER WORLDWIDE

Cervical cancer is the second most common cancer and the third most important cause of cancer mortality worldwide, among women¹. It accounts for approximately 12% of all cancers in women. Every year, 493,000 new cases occur and approximately 274,000 women die from cancer of the cervix⁴.

Since cervical cancer affects predominantly young women, it is an important cause of years of life lost (YLL). It has been estimated that cervical cancer was responsible for 2.7 million YLL in 2000 and it is the primary cause of YLL from cancer in the developing world, representing around 2% of the YLL from all causes of disease. Among women aged between 25 and 64 years, cervical cancer contributes with 2.4 million YLL in developing areas and 0.3 million in the developed countries⁵.

INCIDENCE OF CERVICAL CANCER

Cervical cancer is more frequent in less-developed countries. Southern Africa, South America and South Central Asia have the highest age-standardised incidence rates, over 25 per 100,000 women⁶. The highest incidence rates are reported in Haiti (64 per 100,000 women), Lesotho (46 per 100,000 women) and Bolivia (42 per 100,000 women). The highest absolute number of cases estimated in 132,000 new cases/year is observed in India corresponding to more than one-fourth of the worldwide total⁷.

The age-standardised incidence rate (World reference population) in more developed countries is 10.3 per 100,000 women, approximately half the observed in developing regions¹. In Europe, Finland reported the lowest incidence rate (6.2 per 100,000 women) followed by Malta (7.1 per 100,000 women) and Ireland (8.4 per 100,000 women)².

Trends in cervical cancer incidence have been clearly affected by the practice of screening⁸. In Nordic countries, for example, age-standardised incidence rates of cervical cancer have shown a downward trend since the 1960s decade, demonstrating a decrease from 21.2 per 100,000 in 1966 to 7.6 per 100,000 in 2006². On the other hand, some sub-Saharan African regions have registered an increased incidence in recent years⁹,¹⁰.

SURVIVAL OF CERVICAL CANCER PATIENTS

In developing countries, less than 50% of women affected by cervical cancer survive longer than 5 years, while in developed countries the 5-year survival is about 60%². The latest data from cervical cancer survival for women diagnosed between 1995 and 1999 is available from the EUROCAR-4 project (Table 1). The Eu-
The European average 5-year age-standardised relative survival for cervical cancer diagnosed in 1995–1999 and followed up to December 2003 was 62.6%\(^{26}\), but there is a large heterogeneity across countries, with 5-year age-standardised relative survival ranging from 51.5% in Poland to 68.5% in Malta (Table 1).

In the first half of the 20th century, major improvements in survival from cancer of the cervix were observed, due in part to improving stage at diagnosis, and better results of treatment, particularly as a result of advances in radiotherapy\(^{27,28}\). However, the most recent estimates are not substantially different from those observed in the previous periods covered by the EUROCare projects\(^29\), as shown in Figure 1.

The relative survival of patients with cervical cancer increased by 3%, from the cases diagnosed in the period 1978-1989 [EUROCare-2\(^{33}\)] to the period 1994-1999 [EUROCare-4\(^{30}\)]. The main determinant of cervical cancer prognosis remained the stage at diagnosis and this modest increase in survival rate has been interpreted as being due mainly to earlier diagnosis\(^32\).

CERVICAL CANCER MORTALITY

Approximately 80% of all cervical cancer cases and deaths occur in less-developed countries, where cervical cancer accounts for 15% of female cancers and about 40% of cervical cancer deaths in developing countries occur in South Central Asia, a heavily populated region\(^1\). The highest mortality rates are reported in Lesotho (38 per 100,000 women), Haiti (35 per 100,000 women) and Tanzania (33 per 100,000 women)\(^1\).

The age-standardised mortality rate (World reference population) is 11.2 per 100,000 women almost three times higher than in developed regions\(^{1}\) (Table 2).

The lowest mortality rates in Europe are reported in Southern (5.6 per 100,000 women) and in Northern Europe (5.8 per 100,000 women) (Table 2).

---

**Table 1**

<table>
<thead>
<tr>
<th>Country</th>
<th>Age-standardised 5-year relative survival (95% confidence intervals)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poland</td>
<td>51.5 (48.6-54.6)</td>
</tr>
<tr>
<td>United Kingdom-Wales</td>
<td>54.7 (51.0-58.6)</td>
</tr>
<tr>
<td>Portugal</td>
<td>56.4 (52.4-60.8)</td>
</tr>
<tr>
<td>United Kingdom-Scotland</td>
<td>58.8 (56.1-61.6)</td>
</tr>
<tr>
<td>United Kingdom-Northern Ireland</td>
<td>58.9 (53.8-64.5)</td>
</tr>
<tr>
<td>United Kingdom-England</td>
<td>59.1 (58.1-60.2)</td>
</tr>
<tr>
<td>Ireland</td>
<td>59.7 (55.4-64.4)</td>
</tr>
<tr>
<td>Germany</td>
<td>60.5 (55.3-66.2)</td>
</tr>
<tr>
<td>Spain</td>
<td>62.7 (59.7-65.9)</td>
</tr>
<tr>
<td>Iceland</td>
<td>62.9 (49.5-79.9)</td>
</tr>
<tr>
<td>Slovenia</td>
<td>63.5 (59.9-67.4)</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>63.6 (58.7-69.0)</td>
</tr>
<tr>
<td>Austria</td>
<td>63.7 (61.6-66.0)</td>
</tr>
<tr>
<td>Denmark</td>
<td>64.0 (61.7-66.5)</td>
</tr>
<tr>
<td>Italy</td>
<td>64.7 (63.1-66.4)</td>
</tr>
<tr>
<td>Finland</td>
<td>65.0 (61.2-69.0)</td>
</tr>
<tr>
<td>Belgium</td>
<td>65.1 (61.8-68.6)</td>
</tr>
<tr>
<td>Sweden</td>
<td>66.2 (64.0-68.3)</td>
</tr>
<tr>
<td>Netherlands</td>
<td>66.5 (63.3-69.8)</td>
</tr>
<tr>
<td>Norway</td>
<td>66.7 (63.9-69.5)</td>
</tr>
<tr>
<td>France</td>
<td>66.9 (63.9-70.1)</td>
</tr>
<tr>
<td>Switzerland</td>
<td>68.2 (63.6-73.1)</td>
</tr>
<tr>
<td>Malta</td>
<td>68.5 (51.5-91.2)</td>
</tr>
</tbody>
</table>

**Figure 1**

Age-standardised (European standard population) relative survival (%) of cervical cancer according EUROCARE-3 e -4.

---

Source: Sant M, et al. EUROCARE-4 (2009)\(^{26}\)

Each point represents an European country. Source: EUROCARE-3\(^{30}\) e -4\(^{30}\).
A declining trend in cervical cancer mortality is clearly observed, in developed countries where mainly cervical cytology programme exist. In European Union countries, from 1993 to 2001, a gradual decrease was observed in age-standardised mortality rate, from 3.4 per 100,000 women in 1993 to 2.8 per 100,000 (World population reference). However, in less developed countries, this trend follows the opposite direction. In South Africa, for example, age-standardised mortality rate increased from 9.9 per 100,000 in 1993 to 13.3 per 100,000 in 2005.

### INCIDENCE OF CERVICAL CANCER IN PORTUGAL

Portugal presents the highest rates of cervical cancer in Western Europe, with an incidence rate of 14.8 per 100,000 women and a mortality rate of 4.9 per 100,000 women in 2001, being the fifth most common cancer among women. Approximately 780 new cases occur and 260 women die every year.

Relative 5-year survival in the south of Portugal was 60%, the fourth lowest among other European countries represented in the recent publication of the Registo Oncológico Regional da Região Sul (ROR-Sul).

### INCIDENCE OF CERVICAL CANCER IN THE WORLD

<table>
<thead>
<tr>
<th>Region</th>
<th>Number of deaths</th>
<th>Crude mortality rate (/100,000)</th>
<th>Age-standardised mortality rate (/100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Southern Africa</td>
<td>4455</td>
<td>17.5</td>
<td>22.6</td>
</tr>
<tr>
<td>South America</td>
<td>21402</td>
<td>11.9</td>
<td>12.9</td>
</tr>
<tr>
<td>South Central Asia</td>
<td>86708</td>
<td>11.7</td>
<td>5.0</td>
</tr>
<tr>
<td>South-Eastern Asia</td>
<td>22594</td>
<td>8.4</td>
<td>10.2</td>
</tr>
<tr>
<td>Central and Eastern</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Europe</td>
<td>17198</td>
<td>10.9</td>
<td>7.1</td>
</tr>
<tr>
<td>Northern Africa</td>
<td>6588</td>
<td>7.4</td>
<td>9.8</td>
</tr>
<tr>
<td>Southern Europe</td>
<td>4131</td>
<td>5.6</td>
<td>3.3</td>
</tr>
<tr>
<td>Western Europe</td>
<td>5671</td>
<td>6.1</td>
<td>3.4</td>
</tr>
<tr>
<td>New Zealand</td>
<td>82</td>
<td>4.2</td>
<td>3.2</td>
</tr>
<tr>
<td>Northern Europe</td>
<td>2814</td>
<td>5.8</td>
<td>3.6</td>
</tr>
<tr>
<td>Northern America</td>
<td>5796</td>
<td>3.6</td>
<td>2.3</td>
</tr>
<tr>
<td>Eastern Asia</td>
<td>31314</td>
<td>4.3</td>
<td>3.7</td>
</tr>
<tr>
<td>Australia</td>
<td>249</td>
<td>2.5</td>
<td>1.7</td>
</tr>
<tr>
<td>Western Asia</td>
<td>2118</td>
<td>2.2</td>
<td>2.9</td>
</tr>
<tr>
<td>World</td>
<td>273505</td>
<td>8.9</td>
<td>9.0</td>
</tr>
</tbody>
</table>

incidence over the years and in the northern region no descending trend is observed in the most recent years. For the region covered by ROR-Centro, data is available for both invasive and in situ cervical cancer, with similar trends since 2000. When evaluating the incidence rates for invasive and in situ cervical cancers together, peaks are observed in the mid-nineties and in 2000, which are in accordance with the variation in incidence of all cancers registered by ROR-Centro (Figure 3).

**SURVIVAL OF CERVICAL CANCER PATIENTS IN PORTUGAL**

Population-based data on cancer survival in Portugal is available from the ROR-Sul for the incident cases diagnosed in the years 1990-1994, 1995-1999, and 2000-2001 in the southern region (approximately 40% of the Portuguese population) (Table 3). In Portugal a slight increase in age-standardised relative survival from 55.6% in the years 1990-1994 to 60.0% in 2000/2001 was verified (Table 3).

The 5-year relative survival in the southern region was 60%, placing Portugal in the forth lowest position among other European countries.

The most recent data from ROR-Sul also shows regional differences in 5-years relative survival ranging from 55% in the region of Algarve to 72% in Alentejo.
CERVICAL CANCER MORTALITY IN PORTUGAL

In 1996-1998 cervical cancer was responsible for 4.2% of malignant deaths in Portuguese women\textsuperscript{75}. The crude mortality rate in Portugal, according to estimates from GLOBOCAN 2002, was 7.3 per 100,000 women, preceded by Slovenia with 7.8 per 100,000 and by Denmark with 8.6 per 100,000\textsuperscript{1}.

Between 1988-1990 and 1996-1998, the age-standardised (World reference population) mortality rate decreased from 6.7 per 100,000 women to 5.8 per 100,000 and in the 35-54 age group, corresponding to a -2.7% variation per annum. This variation has been interpreted unlikely to have been due to the effect of cervical screening because mortality in the 35–54 group has not decreased. Probably better access and quality treatment over the previous 10 years explained part of this decrease\textsuperscript{75}.

No overall decline in the age-standardised mortality rate of cervical cancer was observed in Portugal since 1980 (Figure 4).

In women aged between 25 and 79 years mortality from cervical cancer has remained stable between 1980 and 2005 (annual percent change=0.0%, 95%CI: -0.5 to 0.5). The variation was 2.0%/year (95% CI: 0.8 to 3.2) in the age-group 25-44 years, 0.7%/year (95% CI: -0.3 to 1.7) in women aged between 45 and 54 years, 0.4%/year (95% CI: -1.4 to 1.4) in the age-group 54-64 years and 1.6%/year (95% CI: -2.4 to -0.7%) in the age-group 65-79 years\textsuperscript{77}.

In 2005, the lowest age-standardised mortality rates were observed in Alentejo and in the Center region of Portugal with 0.9 per 100,000 women and 2.2 per 100,000 women respectively, areas where regional organised programme are implemented (Figure 5). On the other hand, in Algarve, a region without organised cervical cancer screening it was verified the highest age-standardised mortality rates in Portugal (6.0 per 100,000 women)\textsuperscript{78}.

<table>
<thead>
<tr>
<th>AGE-GROUPS</th>
<th>EUROCARE-3</th>
<th>EUROCARE-4</th>
<th>ROR-Sul 2000/2001</th>
</tr>
</thead>
<tbody>
<tr>
<td>15-44</td>
<td>63.7</td>
<td>68.6</td>
<td>72.0</td>
</tr>
<tr>
<td>45-54</td>
<td>61.0</td>
<td>61.1</td>
<td>63.0</td>
</tr>
<tr>
<td>55-64</td>
<td>65.0</td>
<td>59.1</td>
<td>59.0</td>
</tr>
<tr>
<td>65-74</td>
<td>45.1</td>
<td>43.0</td>
<td>49.0</td>
</tr>
<tr>
<td>≥75</td>
<td>25.0</td>
<td>41.8</td>
<td>28.0</td>
</tr>
</tbody>
</table>

Source: EUROCARE-3\textsuperscript{34}, EUROCARE-4\textsuperscript{35} and ROR-Sul 2000/2001\textsuperscript{36}.
RISK FACTORS FOR CERVICAL CANCER

Epidemiological studies conducted over the past 4 decades have consistently shown that cervical cancer risk is strongly influenced by sexual behaviour: multiple sexual partners, early age at first sexual intercourse, and sexual habits of male partners. Evidence on the causal role of some HPV infections, a sexually transmitted, in the development of cervical cancer are provided by epidemiological studies, supported by molecular technology. Thus, early age at first intercourse and multiple sex partners are associated with a higher risk of HPV infection indirectly increasing the risk of cervical cancer. Case-control studies, case series, and prevalence surveys have unequivocally shown that HPV-DNA can be detected in 95-100% of cases, compared with a prevalence of 5-20% in cervical specimens from a group of women identified as suitable epidemiological controls. Infection with a high-risk HPV type is now considered a necessary cause, though not sufficient, for cervical cancer. Factors such as the number of full-term pregnancies, tobacco smoking and long-term use of hormonal contraceptives may contribute to the progression from cervical HPV infection to cancer.

HPV AND CERVICAL CANCER

Human papillomavirus (HPV) is the cause of genital human papillomavirus infection, a sexually transmitted disease (STD). HPV infection is the most prevalent sexually transmitted infection in the world, especially among young sexually active individuals. It is estimated that approximately 75% to 80% of the sexually active individuals will become infected in their lifetime.

Studies among initially virginal women strongly confirm the sexually transmitted nature of HPV infection. Sexual contact with an infected partner is necessary for transmission, but HPV infections are easily transmitted and it seems that intromissive intercourse is not strictly necessary. HPV DNA has been detected 13% of women who have sex with women. HPV-associated squamous intraepithelial lesions occurred in women who have sex with women, who had never had sex with men.

HPV infects basal epithelial cells, where it exists for a variable period in a non-expressed or latent state. At some point, the virus begins to replicate, by dividing epithelial cells, most commonly causing low-grade cervical lesions as well as vaginal, vulvar, penile lesions, genital warts. Certain types of HPV can cause abnormal cell changes, called dysplasia. Some cases regress or do not progress especially in women under age 35. If this abnormality persists over time and become severe, the cells tend to develop into cancer.

Progression from HPV infection to cancer can take up 5 to 30 years; severe dysplasia can progress to cervical cancer over several years.

HPV INFECTION
Infection is extremely common among women of reproductive age. Most cases remain stable or become undetectable. A small percentage of cases lead to abnormal cell changes (within months or years of infection).

MILD CERVICAL DYSPLASIA
These abnormal cell changes are usually temporary and disappear over time. Some cases, however, progress to severe dysplasia.

SEVERE DYSPLASIA
The precursor to cervical cancer, severe dysplasia is far less common than mild dysplasia. Severe dysplasia can progress from mild dysplasia or, in some cases, directly from HPV Infection.

CERVICAL CANCER
Invasive cancer develops over many years and is most common among women in their 50s and 60s.

Source: Preventing cervical cancer worldwide (88).
Virtually all cases of cervical cancer result from a history of persistent infection with HPV, retaining to a “high risk” subset of this family of viruses. The contribution of HPV DNA in high-grade squamous intraepithelial lesions (morphological precursors of invasive cervical cancer), as indicated by cross-sectional studies of the natural history of cervical cancer, is estimated to be over 85%.

The strength of the association between infection of the cervix with high-risk types of HPV and invasive cervical cancer is almost unprecedented in cancer epidemiology, with odds ratios (OR) over 50 in most studies.

HPV types are stratified into low-, intermediate-, and high-risk categories based on the strength of the association between infection and the occurrence of high-grade and invasive lesions. More than 100 different HPV types have been described, of which approximately 40 types infect the anogenital tract. Among this, about 15 types (HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -68, -73, and -82) are now considered to be of high-oncogenic-risk (HR-HPV). The predominant low-risk types (HPV 6 and 11) cause 90% of genital warts (condyloma acuminata). The most prevalent high-risk types (HPV 16 and 18) cause 70% of cervical cancer and have been found consistently in most case-control studies to be associated with both cervical cancer and carcinoma in situ. In the International Agency for Research on Cancer (IARC) multicentric study, the OR for cervical cancer in women with seven or more full-term pregnancies was fourfold higher than in nulliparous women, and the risk increased linearly with increasing number of full-term pregnancies.

High parity is a consistent risk factor for cervical cancer and has been found consistently in most case-control studies to be associated with both cervical cancer and carcinoma in situ. The evidence on the role of lifestyles related to diet or physical activity in cervical carcinogenesis is too limited to conclude that any aspect of food, nutrition, and physical activity directly modifies the risk of this cancer.

**HPV Vaccination**

Ninety-five percent of all cervical cancers are attributable to HPV infection in the general population. The diseases produced by the oncogenic genotypes of HPV have the potential to be eradicated. Thus, primary prevention of cervical cancer can be achieved through prevention and control of genital infection with oncogenic HPV types.

Recently, prophylactic vaccines have become commercially available, that are based on the recombinant expression and self-assembly of the major capsid protein, L1, into virus-like particles (VLPs) that resemble the outer capsid of the whole virus.

A quadrivalent HPV 16/18/6/11 vaccine was the first to be approved for use in adolescent and young women ages 9 to 26 years for the prevention of cervical cancer (HPV 16 and 18) and genital warts (HPV 6 and 11), as well as vulvar and vaginal precancerous lesions. It is administered as a 0.5 ml intramuscular injection in a three-dose immunization protocol (2 and 6 months after the first dose).
A bivalent HPV 16/18 virus-like particles (VLP) vaccine is also available as a 0.5 ml intramuscular injection in a three-dose immunization protocol at 1 and 6 months after the first dose112.

Bivalent vaccines as well as quadrivalent vaccines have been demonstrated to be safe, immunogenic and effective against type-specific HPV infection10, 113.

In women who have no evidence of exposure or infection with the HPV genotypes that are present in the vaccine, both vaccines show very high efficacy, with over 90% reduction in persistent infection and greater than 98% reduction in high-grade cervical lesions102, 114, 115. Human Papillomavirus vaccines are efficacious in all age groups within the 15-26 years range116.

The progressive development of primary prevention strategies should coexist with secondary prevention of cervical cancer, by means of redesigned screening programs, because vaccination is for pre-exposure prophylaxis; most women will continue to rely on screening117.

Screening and vaccination, adopted in synergy, have the potential to significantly reduce cervical cancer globally. However, in an era of strained health care budgets, even resource-rich countries will have difficulty to support the extra costs of vaccination without some level of re-structuring of their screening programmes118.

Vaccination plus screening should, in theory, prevent almost 100% of cervical cancers, but this could only apply in countries with organised screening programmes, allowing, ensuring an equal coverage of all population groups116.

The gradual extension of vaccination will progressively reduce the costs of the diagnosis and treatment of lesions detected by screening of vaccinated cohorts119. At the beginning of 2008, HPV vaccination had not been implemented in all countries of the European Union. Czech Republic, France, Germany, Greece and Italy had implemented HPV vaccine in the national immunization programme since 2007 and the target population is, respectively, 12-15, 14-25, 12-17, 12-15 years. In 2008, Luxembourg, Portugal, Spain and United Kingdom introduced the vaccine in the national immunization programme for girls with 12-18, 13, 12 and 12-13 years respectively2.

CERVICAL CANCER SCREENING

Cervical cancer is both preventable and curable and is the malignant neoplastic disease for which public health prevention initiatives have had the greatest success119.

Precancerous changes in cervical tissue can persist for years. However, if they are identified and successfully treated early, the lesions will not develop into cervical cancer. Thus, screening women for precancerous changes and treating tissue abnormalities seems to protect women from developing cervical cancer, ultimately decreasing its mortality119.

SCREENING METHODS

Cervical cancer screening started with the introduction of Papnicolaou test into developed countries and it is largely responsible to the remarkable success achieved in cervical cancer prevention. The cervical cytology is a laboratory test developed in the 1940s to detect abnormal cell changes and screening with this method is still considered an integral part of women’s preventive health care in many settings120.

In most routine settings, cervical cytology has a wide range in sensitiveness in detecting cervical neoplasia. In reviews of several studies the sensitiveness to detect high-grade CIN lesions ranged from 47-62% and the specificity from 91-96%121-123. In studies in developing countries the sensitiveness of cervical cytology ranged from 31 to 78 percent and the specific from 91-96%124. This low sensitiveness has been attributed to a combination of poor sample collection (5%-10% of all slides), incorrect slide preparation and laboratory interpretation errors121, 125. False-negative results occur even in optimized screening programs and cannot be entirely eliminated126.

However, conventional cervical cytology test screening has the potential to reduce the risk of developing cervical cancer by 60% to 90% within three years127, and reduction in cervical cancer incidence and mortality in the US and other developed countries has been accomplished despite the relatively low sensitiveness of conventional cytology123.

In England, invasive cervical cancer incidence and mortality rates decreased by approximately 50% from 1988 to 1997, after the introduction of an organised screening program. A similar trend was observed in Norway immediately after the introduction of a national cancer cytology program (cervical cytology test) in 1995127. The extent of this decrease is not generally verified in countries where screening is population-based15.

Liquid-based cytology (LBC) was developed primarily to improve the quality of cervical samples126, 129. This process aims to potentially reduce two important deficiencies observed in conventional cytology: the relatively small and potentially non-representative sample of cells and the effect of other material, including mucous, blood, and other non-cervical cells, on the readability of the slide126. As LBC is more expensive than conventional cytology and requires additional instrumentation, it may not be feasible to implement LBC in low-resource settings124.

Testing cervical specimens for DNA of oncogenic (high-risk) types of human papillomavirus (HPV)
has entered clinical practice, but this test is used mainly to triage for colposcopy those women with cervical cytology tests categorized as "atypical squamous cells of undetermined significance" (ASCUS). HPV testing is more sensitive than cervical cytology testing for identifying cervical cancer and its precursors in population screening. This test is already being incorporated into some screening programs, generally in addition to existing Pap smear screening. HPV testing combined with conventional cytology is more sensitive, yet less specific than cytology alone for both the management of ASCUS and in primary screening.

Although cervical cancer screening, primarily with the cervical cytology smear test, has reduced the incidence of this cancer in industrialized countries, cervical cancer remains the second most common cause of death from cancer in women worldwide, because the developing world has lacked resources to implement widespread, high-quality screening programmes. Countries with low-resource settings perform others screening tests, as visual inspection with acetic acid (VIA) or with Lugol’s iodine (VILI), also known as Schiller’s test. Visual inspection with acetic acid involves swabbing the cervix with an acetic acid and precancerous cells turn white temporally. Applying iodine to the cervix makes precancerous lesions appear well defined, thick, with yellow or brown shaded areas. Recent data show that visual screening with Lugol’s iodine may have higher accuracy than screening with acetic acid. Although adequate training of health providers is required, these tests comprise important advantages because of the relatively simple application, low-cost and rely on little infrastructure.

ORGANISED VERSUS OPPORTUNISTIC CERVICAL CANCER SCREENING

Organised cervical cancer screening accelerated the decline in cervical cancer incidence, in comparison with the trend in areas relying on opportunistic screening.

The term “organised screening programme” is used for screening programmes organised at national or regional level, with an explicit policy, a team responsible for organisation and for health care and a structure for quality assurance. Organised programmes comprise personal invitation to screening to all women in the target age groups at regular time intervals, and all services are provided free of charge. On the other hand, the term “opportunistic screening” refers to cervical cytology testing in asymptomatic women following a recommendation made during a routine medical consultation or a consultation for an unrelated condition for example, on the basis of a possibly increased risk for developing cancer or by self-referral, outside the schedule of an organised programme.

Organised screening provides an equitable distribution of benefits to all women. Strategies must incorporate the needs and perceptions of socially disadvantaged women, and increase their access to screening. It is of extreme importance to provide good quality screening and treatment services that reach women who are at risk.

A good and organised prevention program for cervical cancer must reach a high proportion of women at risk of the disease, also covering the high-risk groups, effectively test these women, treat or manage those who test positive, ensure they are followed-up, monitor and evaluate program impact.

There is strong evidence that well-organised screening with cytology can reduce the incidence and mortality up to 80%. Besides reducing incidence and mortality, increased participation in screening for cervical cancer would also reduce demand for services, thereby reducing the waiting times for cancer services. In countries where wide cervical cancer screening coverage has been achieved cervical cancer incidence and death rates have fallen by more than 50%, being proved as a model for successful cancer prevention.

In the Nordic countries, following the introduction of nationwide screening in the 1960’s, cumulative mortality rates of cervical cancer showed a falling trend. Iceland had observed the greatest fall (84% from 1965 to 1982). In Finland age-standardised (world standard population) mortality rates decreased over 80% from the level of 7.0 deaths per 100,000 women in early 1960s to 1.2 deaths per 100,000 women in the 1990s. In Sweden and Denmark the decline was 34% and 27% between 1965 and 1982, respectively. In Norway, after the introduction of a national cervical cancer cytology program in 1995, age-standardised (World standard population) mortality rates decreased from the level of 3.0 deaths per 100,000 women in 1995 to 1.9 deaths per 100,000 women in 2006.

In England after the introduction of an organised screening program in 1988, the cervical cancer incidence and mortality decreased around 50 from 1988 to 1997.

In Turin, Italy, a decrease of 20%, from 1992 to 1998, on fully invasive cervical cancer incidence was observed after the introduction of an organised programme in an area where opportunistic screening was previously conducted.

CANCER SCREENING IN EUROPE

In most European countries cervical cancer screening started as an opportunistic activity, and it is still predominant in most European countries. Despite
the relatively good level of resources, few national well-organised and documented programs are implemented. A recent report on the state of the art of cancer control structures in European Union countries, Iceland, Norway and Switzerland shows that 8 countries have no organised programs (Bulgaria, Cyprus, Germany, Greece, Latvia, Luxembourg, Malta and Switzerland). Among the remaining, 14 have programmes with national coverage. Participation rate ranges between 10% and 80%, approximately. In Austria, Belgium, France Ireland, Italy, Portugal, Romania and Spain, organised programmes were implemented, but not with national coverage. A heterogeneity of age target population and in screening interval (years) is also observed. The Papanicolaou test is the most frequently used test.

The first countries with organised programme were Finland in 1963, now presenting a national coverage of 97.5%, and a proportion of participation of 71%, followed by Sweden with a 70% participation and 100% of national coverage and by Austria with a regional organised programme launched in 1970 with a participation of 75% of women aged between 20 and 49 years and 50% of women aged 50-69 years.

European Guidelines recommend three to five years screening intervals. The most commonly recommended interval between normal cytological tests is three years. The interval of screening varies among European countries, most of them having programmes with three-year intervals between screening tests, except for Estonia, Finland, Netherlands and Romania that use five years as interval. Sweden and United Kingdom perform 3/5 years screening intervals.

CERVICAL CANCER SCREENING IN PORTUGAL

Cervical cancer screening in Portugal has been predominantly opportunistic and its practice has increased, especially since the early 1990s, mainly by indication from general practitioner or by demand. Population-screening programs on a national scale do not exist. Nevertheless, there are regional organised programs in the Central Region of Portugal, since 1990, in the region of Alentejo, since early 2008, and recently (February 2009) in the North region of the country. The Screening Programme of the Central Region of Portugal is performed by the general practitioners. The cytological smears are collected in the Health Centres and sent to the cytopathology laboratory of the Coimbra Cancer Institute.

The programme being conducted in Alentejo uses liquid based cytology. According to the AdmInistração Regional de Saúde do Alentejo, more than 13,500 women were screened since January 2008.

In the North the cervical cancer screening programme began initially with a pilot phase in Centro de Saúde do Castelo da Maia (February 2009) using the liquid based cytology preceded by HPV testing as methods of screening. This screening programme aims to screen at least 70% of the eligible population.

CONCLUSION

The epidemiology of cervical cancer worldwide is strongly influenced by the existence of effective screening programmes. Cervical cancer incidence and mortality rates have decreased in countries with effective programmes. Furthermore, high incidence and mortality rates are observed in developing countries, which lack nationwide prevention programmes. The removal of incident cases through detection and treatment of pre-malignant lesions and the diagnosis of invasive lesions, at earlier and more curable stages, provide an opportunity to prevent or delay progression to invasive cancer, leading to a reduction in mortality from cancer of the cervix. The identification of oncogenic HPV infections as a necessary cause of cervical cancer has provided new directions for research and two HPV vaccines have been developed. However, early detection will remain the key-element in reducing cervical cancer since vaccination is presently only indicated for pre-exposure prophylaxis and, thus, most women will continue to rely on screening. Primary and secondary prevention strategies should coexist in order to maximize the decrease in cervical cancer incidence and mortality.

REFERENCES

2. The state of the art of cancer control structures in European countries in January 2008. Department of Hygiene and Epidemiology, Porto University Medical School, Portugal National Coordination for the Oncological Diseases, Portugal 2008.